This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Apr 1;4(4):586.

doi: 10.1001/jamaoncol.2016.6786.

Overall Survival vs Disease-Specific Survival

Harry B Burke¹

Affiliations

PMID: 29167882
DOI: 10.1001/jamaoncol.2016.6786

Comment

Overall Survival vs Disease-Specific Survival

Harry B Burke. JAMA Oncol. 2018.

. 2018 Apr 1;4(4):586.

doi: 10.1001/jamaoncol.2016.6786.

Author

Harry B Burke¹

Affiliation

¹ Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland.

PMID: 29167882
DOI: 10.1001/jamaoncol.2016.6786

No abstract available

PubMed Disclaimer

Comment in

Overall Survival vs Disease-Specific Survival-Reply.
Mailankody S, Prasad V. Mailankody S, et al. JAMA Oncol. 2018 Apr 1;4(4):586-587. doi: 10.1001/jamaoncol.2017.3865. JAMA Oncol. 2018. PMID: 29167883 No abstract available.

Comment on

Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
Mailankody S, Prasad V. Mailankody S, et al. JAMA Oncol. 2017 Jul 1;3(7):889-890. doi: 10.1001/jamaoncol.2016.5296. JAMA Oncol. 2017. PMID: 27892992 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations